Together, these results show that TRAP1 may be a potential therapeutic target for neurodegenerative diseases such as ALS, where mitochondrial dysfunction has been shown to be an early marker of pathogenesis. This evidence concerns the gene TRAP1 and amyotrophic lateral sclerosis.